Skip to main content

NCT00211133 - A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects Receiving Chemotherapy

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects Receiving Chemotherapy

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.


CSR Summary

Not Available


Data Specification

Not Yet Available


Annotated CRF

Not Yet Available

Product Info

Generic Name
Epoetin alfa
Product Name
PROCRIT®
Therapeutic Area
Blood and Lymph Conditions
Enrollment
939
Product Class
Colony-stimulating factors
Sponsor Protocol Number
CR004414 (EPO-INT-76) DOUBLE BLIND
Data Holder
Johnson & Johnson
Condition Studied
Anemia, Neoplasms, Breast

Supporting Documentation

Analysis Datasets
Annotated Case Report Form (CRF)
Clinical Study Report
Data Definition Specification
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

APPROVED DATA REQUESTS ASSOCIATED WITH THIS TRIAL

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.